Follicular Lymphoma And Mantle Cell Lymphoma

The book is dedicated to Follicular lymphoma and Mantle cell lymphoma and highlights major reference works that contributed significantly to the understanding of these two lymphomas. The aim is to bring the basic science adjacent to the applied science. There is significant focus on the biology of normal B cell development that forms the basis for understanding the pathobiology of these entities. This text is designed to provide a concise yet comprehensive summary of traditional and newer entities, prognostic markers, pathobiology and newer classifications based on molecular genetics/chromosomal abnormalities. The chapters are written by practicing hematopathologists, molecular pathologists, dermatopathologists and clinical haematologists with an emphasis on practical approaches to these entities. The newer technologies and their practical applications are elaborated in an easy-to-comprehend format. Follicular Lymphoma and Mantle Cell Lymphoma is an approachable read for residents and fellows and clinically relevant to practicing pathologists and hematologists. It also serves as a valuable resource for anyone with an interest in B cell lymphomas.

This book provides a comprehensive, state-of-the-art overview of follicular lymphoma. The first section of the text explores the current understanding of the biology and pathogenesis of follicular lymphoma, through reviewing recent changes in the WHO classification of low-grade lymphomas, current diagnostic techniques, and emerging research on the importance of the immune microenvironment. The second section focuses on current treatment for localized disease, advanced stage disease, and transformed follicular lymphomas, and details currently FDA approved regimens and evolving radiation techniques for early stage and advanced disease. The last section of the text presents emerging approaches in targeted, immunologic, and vaccine therapy. Written by experts in the field, Follicular Lymphoma: Current Management and Novel Approaches is a valuable resource for practicing clinicians, practitioners, and researchers who manage and have an interest in follicular lymphoma.

This first open access European CAR-T Handbook, co-promoted by the European Society for Blood and Marrow Transplantation (EBMT) and the European Hematology Association (EHA), covers several aspects of CAR-T cell treatments, including the underlying biology, indications, management of side-effects, access and manufacturing issues. This book, written by leading experts in the field to enhance readers’ knowledge and practice skills, provides an unparalleled overview of the CAR-T cell technology and its application in clinical care, to enhance readers’ knowledge and practice skills.

This book provides a comprehensive overview of current treatment strategies in indolent lymphomas, the clinical management of which continues to pose significant challenges for the general oncologist despite the tremendous progress in diagnosis, evaluation of risk factors, and molecular targeted approaches. Experts in the field from around the world describe the histomorphology in a clinically relevant manner, consider the role of risk factors in detail, and discuss the full spectrum of therapeutic approaches. Special emphasis is placed on the translation of molecular science into clinical care, and a disease-specific algorithm is proposed for each entity. The coverage encompasses follicular lymphoma, MALT, nodal marginal zone lymphoma, splenic marginal zone lymphoma, Waldenström’s macroglobulinemia, hairy cell leukemia, chronic lymphocytic leukemia, mycosis fungoides, large granular lymphocytic leukemia, and also mantle cell lymphoma. The book will be an excellent resource for experienced and inexperienced practitioners alike.

Thoroughly updated for its Second Edition, Non-Hodgkin Lymphomas is the definitive textbook on the biology, diagnosis, staging, and treatment of all forms of non-Hodgkin lymphomas. With backgrounds in medical and radiation oncology, molecular biology, and pathology, the editors and contributors provide an international, multidisciplinary approach to the topic. This edition is the first text using the new World Health Organization classification of non-Hodgkin lymphomas. The book offers complete coverage of the most current techniques for diagnosis, staging, and treatment, the approach to specific types of lymphoma, and special problems common to the management of patients with these disorders.

This is a comprehensive textbook of Hodgkin's and non-Hodgkin's lymphomas written by leaders in the field of childhood lymphomas. It includes clinical, pathologic and molecular biology of each subtype of lymphoma. The pathology chapters are comprehensive and include excellent photographs. The book is at the level of subspecialists in pediatric hematology and oncology, radiation oncology, pediatric surgery and hematopathology.

Mantle cell lymphoma (MCL) is a subtype of Non-Hodgkin's Lymphoma (NHL) with varying clinical presentations, ranging from indolent disease to highly aggressive symptoms. MCL represents approximately 3-10% of non-Hodgkin lymphomas, and has increased in incidence over the past several decades. The majority of patients respond to initial therapy, but remission duration is typically short. This book discusses the clinical characteristics of mantle cell lymphoma, as well as its prevalence and examines several treatment options available.

This issue of Hematology/Oncology Clinics, guest edited by Dr. Caron A. Jacobson, with consulting editors George P. Canellos and H. Franklin Bunn, will focus on Non-Hodgkin’s Lymphoma. Topics include, but are not limited to: Ontogeny, Genetics, Molecular Biology and Classification of B and T cell Non-Hodgkin’s Lymphoma; Diffuse large B cell lymphoma and high grade B cell lymphoma; Burkitt lymphoma and other highly aggressive B cell lymphomas; CNS lymphoma; Mantle cell lymphoma; Follicular lymphoma; Marginal zone lymphoma and lymphoplasmacytic lymphoma; Non-cutaneous T cell lymphoma; Cutaneous T cell lymphoma; Transplant and other adoptive immune cell therapies for non-Hodgkin lymphoma; Non-cellular immune therapies for non-Hodgkin’s lymphoma; and Targeting biology in non-Hodgkin’s lymphoma.